info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
9
Jun
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
18
May
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13
May
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
13
May
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
11
May
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10
May
CymaBay Names Lewis Stuart Chief Commercial Officer
6
May
CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
5
Apr
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
25
Mar
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
12
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
<< Previous
1
2
3
4
5
6
7
8
9
10
...27
Next >>
Show All
Scroll
